TY - JOUR

T1 - Promising pessimism

T2 - reading the futures to be avoided in biotech

AU - Tutton, Richard

PY - 2011/6

Y1 - 2011/6

N2 - A number of science and technology studies (STS) scholars have suggested that the performativity of the 'forward-looking statement' is an important institutional element of contemporary biocapital. This paper considers how, when making projections that set up expectations about their futures, firms also acknowledge and detail the risk factors that they face in their operations. In other words, in addition to projecting optimistic scenarios, firms advance much more pessimistic images of futures that they wish to avoid: possible failures, disappointments and financial losses. I examine such pessimistic projections in company filings to the US Securities and Exchange Commission (SEC) and investigate their discursive character. I ask what value such pessimism might hold for STS scholars interested in the mangle of science and capital. I sample the SEC filings of three companies: deCODE Genetics, DNAPrint Genomics Inc. and NitroMed Inc. In their own particular ways, these projections exemplify the volatility and the promise of the life sciences in the 21st century. My reading shows that such pessimistic risk factor statements provide interesting commentary on the dynamics of risk and innovation in the context of contemporary biocapital, raising questions to which analysts to date have given little attention.

AB - A number of science and technology studies (STS) scholars have suggested that the performativity of the 'forward-looking statement' is an important institutional element of contemporary biocapital. This paper considers how, when making projections that set up expectations about their futures, firms also acknowledge and detail the risk factors that they face in their operations. In other words, in addition to projecting optimistic scenarios, firms advance much more pessimistic images of futures that they wish to avoid: possible failures, disappointments and financial losses. I examine such pessimistic projections in company filings to the US Securities and Exchange Commission (SEC) and investigate their discursive character. I ask what value such pessimism might hold for STS scholars interested in the mangle of science and capital. I sample the SEC filings of three companies: deCODE Genetics, DNAPrint Genomics Inc. and NitroMed Inc. In their own particular ways, these projections exemplify the volatility and the promise of the life sciences in the 21st century. My reading shows that such pessimistic risk factor statements provide interesting commentary on the dynamics of risk and innovation in the context of contemporary biocapital, raising questions to which analysts to date have given little attention.

KW - anticipation

KW - biocapital

KW - futures

KW - promise

KW - sociology of expectations

KW - EXPECTATIONS

KW - TECHNOLOGY

KW - SOCIOLOGY

KW - BIDIL

KW - PHARMACEUTICALS

KW - REVOLUTION

KW - PROSPECTS

KW - GENETICS

KW - IMPACT

KW - MYTH

U2 - 10.1177/0306312710397398

DO - 10.1177/0306312710397398

M3 - Journal article

VL - 41

SP - 411

EP - 429

JO - Social Studies of Science

JF - Social Studies of Science

SN - 0306-3127

IS - 3

ER -